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Oral cancer is one of the drastic human cancers due to its aggressiveness and high mortality rate. Of all oral cancers, squamous
cell carcinoma is the most common accounting for more than 90%. Epithelial-mesenchymal transition (EMT) is suggested to play
an important role during cancer invasion and metastasis. Recently, emerging knowledge on EMT in carcinogenesis is explosive,
tempting us to analyze previous studies on EMT in oral squamous cell carcinoma (OSCC). In this paper, we have ﬁrst addressed
the general molecular mechanisms of EMT, evidenced by alterations of cell morphology during EMT, the presence of cadherin
switching,turningonandturningoﬀofmanyspeciﬁcgenes,theactivationofvarioussignalingpathways,andsoon.Theremaining
part of this paper will focus on recent ﬁndings of the investigations of EMT on OSCC. These include the evidence of EMT taking
placeinOSCCandthesignalingpathwaysemployedbyOSCCcellsduringtheirinvasionandmetastasis.Collectively,withthelarge
body of new knowledge on EMT in OSCC elaborated here, we are hopeful that targeting treatment for OSCC will be developed.
1.Introduction
Epithelial-mesenchymal transition (EMT) is considered a
reversibly biologic process that is important for normal
embryogenesis and organ development from single-layered
to multilayered organisms, particularly during gastrulation
and neural crest cell migration [1]. The neural crest cells,
originated from nonneural ectodermal cells that are situated
above the neural tube, can migrate from the ectodermal layer
throughthedisruptedbasallaminabyacquiringthecomplex
processofEMT.Inthisprocess,theneuralcrestcellswillulti-
mately change their epithelial phenotype to the ﬁbroblast-
like morphology and eventually migrate to a distant site to
form new organs. Once reaching their destinations, where
they become diﬀerentiated into diﬀerent cell types, they are
likely to undergo the reverse process, called mesenchymal-
epithelial transition (MET) that involves the conversion of
mesenchymalbacktoepithelialcells.Therefore,theepithelial
cells appear to be plastic and are able to change back and
forth between EMT and MET. One of the best-studied and
-known processes of EMT is the breakdown of intercellular
adhesion between epithelial cells by inhibiting expression
of E-cadherin (epithelial cadherin), whereas the cells that
undergo the EMT process aberrantly express higher levels of
N-cadherin (mesenchymal cadherin). This process is called
“cadherin switching” [2, 3], which will be discussed later in
this paper.
In addition to the importance of EMT process during
the prenatal development, EMT is a natural process that can
be found in several pathophysiological conditions in human
adults. Particularly, EMT is a necessary component of the
inﬂammatory process and normal wound healing in adult-
hood [4]. However, dysregulated EMT in the inﬂammatory
process and wound healing can pathologically result in scar
formation and then lead to ﬁbrotic lesions in human organs,
especially in kidney [5]. By analogy to the EMT process
undertaken by the neural crest cells, the delamination of
malignant cells that undergo metastasis and invasion into
adjacent underlying tissue from the primary tumor can also
exploitthisprocess.Accordingly,ithasbeendemonstratedby
a great number of studies that the process of EMT is linked
with cancer cell metastasis and invasion, which directly
correlates with poor prognostic markers. These include poor
tumor staging, an increased risk of cancer recurrence, and2 ISRN Oncology
a decreased survival rate in several types of cancers, such as,
breast cancer [6], colorectal cancer [7, 8], gastric cancer [9],
bladder cancer [10], and lung cancer [11, 12]. Nevertheless,
the transient nature and diﬀering degrees of cells undergoing
EMT events that occur only in some cancer cellsat the tumor
front,whileothercancercellsstillretaintheirepithelialtraits,
make scientiﬁc investigation of this phenomenon in vivo
diﬃcult.Therefore,muchofwhathasbeenlearnedaboutthe
EMTisderivedfrominvitrostudiesthathavebeencorrelated
with clinical observations in tumor specimens.
The phenomenon of EMT can be simply divided into 3
distincttypes[13],includingthetype1EMTinembryogene-
sis,thetype2EMTinthewoundhealing,tissueregeneration,
and organ ﬁbrosis, and the type 3 EMT in cancer cell
metastasis and invasion. In the type 3 EMT, several markers
of EMT in cancer specimens have been associated with the
presence of metastasis, the increased recurrence rate, and the
decreased survival rate, supporting the concept that several
events taking place in the type 3 EMT represent aggressive
behavioral changes of cancer cells. As more knowledge
accumulated from studies in the EMT area, we will have
a better insight into the similarities and diﬀerences among
these three types of EMT in the future. In this paper, an
overview of our current understandings of the type 3 EMT at
the molecular level will be delineated, including loss of cell to
celladhesionbyactivationoftranscriptionalrepressors,actin
reorganization and formation of invadopodia, expression of
relevant matrix metalloproteinases (MMPs), and changes in
the expression of microRNAs. In addition, some evidence
derived from our study in oral squamous cell carcinoma
(OSCC)tissuesandcelllineswillbedemonstratedtosupport
the EMT concept for the aggressiveness of OSCC. It is
recommended that the readers consult other reviews of the
literature for more details of the type 1 and type 2 EMT
[13–15].
2. Loss of Cell-to-Cell
Adhesion by TranscriptionalRepressors
andIts Consequences
The loss of cell to cell adhesion, triggered by activation
of an EMT program, together with subsequent cell-ECM
adhesions mediated by integrins, like β4, α5β1, and αVβ6
[16], is among the ﬁrst critical steps of cancer metastasis,
invasion, and progression. Several reports have shown the
acquisitionofmesenchymal markersin carcinoma cells,such
as vimentin, N-cadherin, and ﬁbronectin, with the concomi-
tant loss of epithelial E-cadherin, a major constituent of the
adherens junctions, in the processes of EMT. Consequently,
E-cadherin is considered to be a “master regulator” of EMT.
Furthermore, the connection between loss of E-cadherin
expression in cancer cells and poor patient prognosis,
including increased tumor grade, metastasis, and mortality,
has been established by several studies. There are a number
of causative factors that can result in functional loss of E-
cadherin during tumor progression in epithelial carcinoma.
These include mutations of E-cadherin in germ-line and
somatic cells, chromosomal aberrations, DNA hypermethy-
lation of the E-cadherin gene, transcriptional suppression
of E-cadherin by several transcriptional repressors whose
activities are induced by growth factors, and the cleavage of
E-cadherin by proteinases [17]. It is interesting to note that
the existence of genetic mutations of E-cadherin is extremely
rare in almost every type of cancer, whereas the epigenetic
modiﬁcation by DNA hypermethylation of the promoter
region of E-cadherin gene is more frequently found and
responsible for the EMT process in cancer cells [17].
There are several growth factors, probably emanating
from tumor-associated stromal cells, that induce the loss of
E-cadherin expression/function and then cancer cell migra-
tionandinvasion,includinginterleukin-6[18],transforming
growth factor β (TGFβ)[ 19], hepatocyte growth factor and
its receptor, Met [20] ,e p i d e r m a lg r o w t hf a c t o r[ 21], insulin-
like growth factor [22], and ﬁbroblast growth factor (FGF)
[23]. For instance, upon induction of EMT by TGFβ,a n
increase in DNA methylation of the E-cadherin that prevents
the transcription of E-cadherin gene has been observed,
w h e r e a sw i t h d r a w a lo fT G F β promotes a reversion of EMT
process by triggering the reexpression of E-cadherin [24].
Other possible signaling mechanisms of TGFβ that are
associated with EMT include the activation of Sma and
mothers against decapentaplegic (Smad) proteins (Figure 1)
that facilitate cell motility and autocrine production of
TGFβ, which can further enhance the EMT program [25,
26], and the activation of mitogen-activated protein kinase
(MAPK) and PI3K/Akt pathways independent of Smad
activation [27]. Consistently, a better prognosis of mice in
the model of skin and colon cancers has been obtained from
the deﬁciency of TGFβ receptor expression [28, 29].
Upon binding to their putative receptors, these growth
factors can activate the intracellular signaling pathways that
activate several transcriptional repressors of E-cadherin gene
transcription, such as Snail, Slug (now called Snail2) [30–
32], zinc ﬁnger E-box binding homeobox (ZEB) 1, ZEB2,
and Twist (a transcription factor known to drive EMT and
metastasis) [33, 34]. Binding between these repressors and
the E-cadherin gene promoter can lead to the epigenetic
silencing of E-cadherin expression in a number of ways. For
example, the Snail, a member in the family of zinc-ﬁnger
transcription factors that is proven to be a master gene for
EMT, induces the activity of histone deacetylase enzymes
to remove the acetyl groups from the histone proteins,
resulting in a high-aﬃnity binding between histones and
DNA, which prevents the transcription of E-cadherin gene
[35]. Furthermore, the histone deacetylation can enhance
the binding between polycomb repressor complex 2 and
DNA, causing DNA hypermethylation that can suppress
the E-cadherin gene transcription [36]. Otherwise, Snail
may upregulate ZEB1 expression, which further inhibits E-
cadherin expression. Consistent with the inhibitory eﬀect of
SnailonE-cadherinexpression,areversecorrelationbetween
the expression of E-cadherin and that of Snail has been
demonstrated in patients suﬀering from OSCC [37]. As
with the inhibitory eﬀect of Snail on E-cadherin expres-
sion, forced overexpression of Slug markedly reduces E-
cadherin expression, while signiﬁcantly enhances expression
of MMP2, resulting in tumor metastasis in vivo [11].ISRN Oncology 3
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Figure 1: The pivotal role of E-cadherin, β-catenin, and transforming growth factor β (TGFβ) and Wnt signaling pathways in an
epithelial-mesenchymal transition (EMT) program. Upon loss of E-cadherin expression, β-catenin, which colocalizes with E-cadherin at the
cytoplasmic membrane, is released and accumulated in the cytoplasm. Under normal circumstances, liberated β-catenin is rapidly degraded
by proteasomes in the adenomatous polyposis coli (APC)/axin/glycogen-synthase kinase 3β (GSK3β) complex. However, as in several cases
of cancers, APC is not functional or the activity of GSK3β is diminished by the activation of Wnt signaling pathway, β-catenin can migrate
to the nucleus, where it functions as a cofactor for the transcription factor T-cell factor (TCF) and potentiates its transcriptional activity in
concert with the phosphorylated SMAD 2 and 3, triggered by TGFβ signaling, leading to tumor proliferation, EMT, migration, and invasion.
Similar to β-catenin, p120-catenin can translocate into the nucleus, where it binds to the transcriptional repressor Kaiso to deactivate this
protein, causing the unknown genes to become activated by derepression. GFs: growth factors; RTK: receptor tyrosine kinase; TGFβR: TGFβ
receptor.
An impairment of E-cadherin function can occur from
proteolytic cleavage by γ-secretase and a disintegrin and
metalloproteinase (ADAM) 10 that generates E-cadherin
fragments both inside and outside the cell [38, 39]. It
has been shown that the shed extracellular domain of E-
cadherin interferes with the cell to cell adhesion, enhancing
cell detachment and then migration [40]. In addition, the
cytoplasmic fragment of E-cadherin can translocate into the
nucleus, where it modulates the activity of transcriptional
repressor, Kaiso, which exerts its suppressive activity on the
promoterregionoftargetgenesthatarestilllargelyunknown
[41].BesidestheproteolyticcleavageofE-cadherin,degrada-
tion of E-cadherin in the adherens junctions by endocytosis,
ubiquitination, and subsequent proteasomal degradation
has been shown by phosphorylation of E-cadherin upon
activation of receptor tyrosine kinases (Figure 1), such as
growth factor receptors, and nonreceptor tyrosine kinase Src
[42].
Subsequent to loss of E-cadherin function, which results
in the disruption of adherens junctions and the loss of cell
polarity, β-catenin, which colocalizes with E-cadherin to the
cytoplasmic membrane, is critical for linking intercellular
adherens junctions with the intracellular actin microﬁla-
ment, and plays an essential role in the canonical Wnt
signaling pathway, will be released and accumulated in the
cytoplasm(Figure 1).Undernormalcircumstances,liberated
β-catenin is quickly phosphorylated by glycogen-synthase
kinase 3β (GSK3β) in the adenomatous polyposis coli
(APC)/axin/GSK3β complex and subsequently destroyed by
ubiquitination at the proteasomes (Figure 1)[ 43]. However,
as commonly found in several cases of cancers, whereby
the tumor suppressor APC is not functional or the activity
of GSK3β is diminished by the activation of Wnt signaling
pathway, an excessive amount of β-catenin in the cytoplasm
can migrate to the nucleus, where it functions as a cofactor
for the transcription factor T-cell factor (TCF) and potenti-
ates its transcriptional activity in concert with the activated
SMAD 2 and 3, triggered by TGFβ signaling (Figure 1)
[44]. This results in upregulated expression of a number of
target genes required for tumor proliferation, migration, and
invasion, such as c-Myc, cyclin D1 and D2, Slug, matrilysin,
vimentin, and ﬁbronectin [45–48]. Accordingly, shuttling of
β-cateninfromthecytoplasmicmembranetothenucleushas
beendetectedinseveraldiﬀerentsolidtumorsandcancercell
lines, indicating that β-catenin plays a pivotal role in EMT
regulation.
In addition to β-catenin, p120-catenin, which is also
located in the E-cadherin complex, can be released and4 ISRN Oncology
accumulated in the cytoplasm upon the dissociation of this
complex (Figure 1). It has been demonstrated that p120-
catenin can down-regulate the enzymatic activity of RhoA,
but instead upregulate the activity of Rac and Cdc42 [49,
50]. These three GTPase enzymes function in regulating
actin assembly and play an important role in the stability
of cell-cell adhesion by RhoA, and the cell migration and
the formation of migratory membrane protrusions, like
lamellipodia by Rac and ﬁlopodia by Cdc42. Consequently,
liberated p120-catenin can cause the instability of cell-cell
adhesionandinducecellmigrationthroughtheformationof
lamellipodia and ﬁlopodia. Moreover, similar to β-catenin,
p120-catenin can translocate into the nucleus, where it
binds to the transcriptional repressor Kaiso to deactivate
this protein, causing the target genes to become activated by
derepression (Figure 1)[ 51]. However, the target genes for
the p120/Kaiso complex have not yet been deﬁned.
3. Formation of Invadopodia
Lamellipodia and ﬁlopodia are alternatively deﬁned as
invadopodia, whose role is related to ECM degradation and
cell migration, since they contain MMPs that are responsible
for ECM degradation as well as regulation of extracellular
signalingcascades[52].Itisinteresting tonotetheformation
of invadopodia in cancer cells of head and neck squamous
cell carcinoma that undergo EMT [53]. Among the MMPs,
membrane type 1-matrix metalloproteinase (MT1-MMP or
MMP-14) plays an essential role in cell invasion and migra-
tion [54]. MT1-MMP expression was originally reported in
lung carcinoma and stromal ﬁbroblasts near the advancing
tumor front [55]. Subsequently, similar patterns of MT1-
MMP expression have also been described in several other
carcinomas, such as colon, breast, bladder, head and neck,
and cervical cancers. One of the main functions of MT1-
MMP is to cleave and activate the latent form of MMP-2 into
the active form. Correspondingly, the presence of both MT1-
MMP and the active form of MMP-2 often correlates with
poor patient prognosis [54].
4. CadherinSwitching
The cadherin switching from E-cadherin to N-cadherin
expression during EMT appears to provoke cell migration
and invasion and correlates with poor prognosis [56, 57].
It has been demonstrated that the transcriptional repressor
Twist is involved with the induction of N-cadherin in
addition to its suppressive eﬀect on E-cadherin expression
[58, 59]. The aggressive behaviors of cancer cells during
the cadherin switching may be explained by the ﬁndings
that show the interactions between N-cadherin and platelet-
derived growth factor receptor (PDGFR) [60] and between
N-cadherin and ﬁbroblast growth factor receptor (FGFR).
The interaction between N-cadherin and PDGFR is known
to induce several cellular events important for EMT, includ-
ing actin reorganization, proliferation, and migration [61],
whereas the interaction between N-cadherin and FGFR
can prevent the internalization of FGFR upon binding to
FGF, resulting in a prolonged MAPK activation as well
as increased mobility, MMP secretion, and invasiveness of
cancer cells [62]. Moreover, N-cadherin itself can upregulate
the expression of FGFR, resulting in cellular resistance to
apoptosis among metastasized cells that dissociate from the
epithelium [63].
As with the proteolytic cleavage of E-cadherin, the prote-
olytic processing of N-cadherin by ADAM10 and γ-secretase
can generate a shed extracellular domain and an intracellu-
lar fragment, potentially possessing a signaling function as
well. It has been revealed that the cytoplasmic fragment of
N-cadherin can bind to transcription factor cyclic AMP-
responsive element binding protein and induce its degra-
dation at the proteasomes [64]. Nevertheless, the actual
consequence of this repression by the cytoplasmic fragment
of N-cadherin to tumor metastasis and invasion is still
unknown.
5.Signiﬁcanceof MicroRNAs inEMT
Expression of diﬀerent types of noncoding microRNAs has
been reported to act both as a facilitator and as an inhibitor
of the EMT program. For instance, microRNA 200 and
microRNA 205 can block the suppressive activity of tran-
scriptional repressors of E-cadherin expression, including
ZEB1 and ZEB2, thus retaining the epithelial characteristics
of breast cancer, whereas lack of microRNA 200 is implicated
in the promotion of EMT by up-regulating vimentin expres-
sion and diminishing E-cadherin expression in breast cancer
cells [65–68]. On the contrary, microRNA 21 acts in the
opposite direction by facilitating TGFβ-induced EMT [69].
Consequently, it is interesting to further investigate the role
of these microRNAs in the EMT program of OSCC.
6. EMT inOSCC
Oral squamous cell carcinoma is one of the major leading
cancersworldwide.TheincidenceofOSCCremainsconstant
but appears increased in some parts of the world [70,
71]. Although OSCC is relatively easily accessible to early
diagnosisandtreatment,themortalityrateisstillhighdueto
the failure to control tumor recurrence and metastasis. The
overall ﬁve-year survival rate for oral cancer is considerably
lower than other cancers and has not signiﬁcantly changed
during the last two decades. Recently, novel treatments,
aiming to target speciﬁc molecules, aberrantly expressed
during OSCC carcinogenesis, have been investigated and
tested in clinical trials at several research settings with
promising results. These treatments oﬀer hope for replacing
conventional modalities considered nonspeciﬁc and caused
unwanted severe complications in patients.
EMT is the process by which epithelial cells adopt a
mesenchymal phenotype or ﬁbroblast-like properties. The
epithelial cells undergoing EMT involve reorganizing their
cytoskeleton, stretching out, and breaking connections with
their neighbors. After they have completed the transition,
those cells dissolve the extracellular matrix that restrains
them and start spreading to the surrounding tissue. InISRN Oncology 5
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Figure 2: Western blot analysis of expression for vimentin and E-
cadherin proteins in whole cell lysates. Up-regulation of vimentin
protein was evidently demonstrated in HN008 and HN5 cell
lines, while E-cadherin protein was down-regulated in all ﬁve oral
cancer cell lines in comparison with a normal oral keratinocyte
cell line in the presence or absence of stimulation with 10μg/mL
of the cell wall extract of Fusobacterium nucleatum (FnCW), a
gram-negative periodontal bacterium, or 10ng/mL of PMA (a
phorbol ester and epithelial activator) overnight. Expression of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), serving as a
housekeeping gene control, was approximately equivalent among
diﬀerent samples, indicating equal loadings. The molecular weight
of each protein was as predicted.
general, cells proceeding EMT exhibit down-regulation of
many epithelial markers, including E-cadherin, desmopla-
kin, cytokeratins, claudins, occluding, and beta-catenin, and
up-regulationofmesenchymalmarkers,includingN-cadher-
in, vimentin, ﬁbronectin, and Snail-1/2 [72–74]. Morpho-
logically, cancer cells undergoing EMT switch their epithe-
lial characteristics (cobblestone-like, nonmotile and nonin-
vasive) to their mesenchymal elongated, motile, and inva-
sive characteristics [75]. Very recently, we have found
down-regulation of E-cadherin and MMP-9, the epithelial
phenotypes, and up-regulation of vimentin and MMP-2,
the mesenchymal phenotypes, in OSCC cell lines (Figures
2 and 3). Vimentin, in particular, was immunolocalized in
the cytoplasm of OSCC cells at the invasive tumor fronts
(Figure 4).
Cadherin switching, the loss of E-cadherin expression
and the gain of N-cadherin expression, is a crucial event
of EMT in human cancers. As mentioned earlier, Snail is
a master gene in regulating E-cadherin during the process
of EMT. In an OSCC model, Snail-transfected cells showed
completeEMTphenotypeswithaﬁbroblast-likeappearance,
vimentin ﬁlaments, E-cadherin/N-cadherin switching, and
lackofhemidesmosomes[76].Additionally,ZEB-1andZEB-
2 were upregulated in these cells. In a head and neck SCC
(HNSCC) model, the immunohistochemical results revealed
high expression of N-cadherin in the majority of HNSCC
cases and the expression of N-cadherin signiﬁcantly cor-
related with malignant behaviors [77]. Cadherin switching
was found in 30 of 80 HNSCC cases and correlated with
histologic diﬀerentiation, pattern of invasion, and lymph
nodes metastasis. HNSCC cells also showed cadherin switch-
ing with EMT features. Similarly, spindle cell carcinoma
(SpCC), a biphasic tumor composed of conventional SCC
and a malignant spindle cell component, demonstrated
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Figure 3:GelatinzymographyshowsMMP-9andMMP-2activities
in the culture medium of control and stimulated normal oral
epithelial cells (HOK) and two oral cancer cell lines (HN6 and
HN15) with 10ng/mL of PMA or 10μg/mL of F.n.CW. The result
showed that the phenotype of two oral cancer cell lines was indeed
transformedintomesenchymalcells,inwhichtheypossessedhigher
MMP-2, but less MMP-9, activities than normal oral epithelial cells
(HOK). Interestingly, unlike normal oral epithelial cells, there was
no alteration in terms of MMP-2 and MMP-9 activities in HN6 and
HN15 stimulated with either F.n.CW or PMA when compared to
normalcellsstimulatedwithPMA(HOK+PMA).Thegelatinolytic
activities of puriﬁed MMP-2 and MMP-9 are shown on the two left
columns.
cadherin switching [78]. The majority of cases of SpCC with
metastasis also exhibited high expression of N-cadherin.
As mentioned earlier, the integrin has been found to play
an important role in EMT. The αVβ6 integrin, in particular,
was postulated to modulate EMT in OSCC [79]. When
the full length β6 integrin was expressed in poorly invasive
OSCC cells, OSCC cells increased expression of vimentin
and reduced expression of keratin and E-cadherin, while
OSCC cells with the expression of the truncated form of
β6 subunit retained their epithelial characteristics and did
not alter vimentin or E-cadherin expression. In addition,
the β6 integrin increased MMP-3 activation and tenascin-C
expression. Notably, both molecules were MEK dependent.
7. What SignalsEMT inOSCC?
Activation of the PI3K/Akt signaling pathway is a frequent
event in human cancers, including OSCC (Figure 5)[ 80,
81]. Particularly, Akt-1 and Akt-2 were overexpressed in
OSCC (Figure 5). Previous studies have shown involvement
of PI3K/Akt signaling pathway in EMT of SCC. In an in vitro
model of laryngeal SCC, epidermal growth factor (EGF) was
suggested as an inducer for EMT [82]. Upon stimulation
of epidermal growth factor receptor (EGFR) with EGF,
SCC cells increased motility, migration, and invasion and
underwent EMT with down-regulation of E-cadherin and
up-regulation of N-cadherin and vimentin. Moreover, it was
found that MMP-9 mediated degradation of E-cadherin into
asolubleform.WiththeuseofinhibitorsofEGFR,PI3K,and
MEK-1/2, EMT appeared to occur independently through6 ISRN Oncology
(a) (b)
Figure 4: Immunohistochemical study on OSCC tissue showing that some epithelial cells at the invasive tumor fronts with the brown
positive staining underwent EMT by increased cytoplasmic production of vimentin (arrowheads in (b)). (b) is a higher magniﬁcation view
from an inset in (a).
(a) (b)
Figure 5: Immunohistochemical study on the expression of Akt1 and Akt2 from sections of an OSCC sample. Intense cytoplasmic staining
of both Akt1 (arrowheads in (a)) and Akt2 (arrowheads in (b)) is observed in the tumor cells, while the overlying epithelium is principally
negatively stained.
two signaling pathways: PI3K/Akt and MEK-1/2/ERK-1/2
pathways.
Similarly, an activation of the PI3K/Akt signaling path-
way was shown to be an important feature of EMT in
OSCC. The role of Akt in the biology of OSCC was
investigated by employing OSCC lines engineered to express
constitutivelyactiveAkt[74].TheresultsrevealedthatOSCC
cellsunderwentEMTcharacterizedbydown-regulationofE-
cadherin, desmoplakin, and beta-catenin and up-regulation
of vimentin. Morphologically, OSCC cells lost epithelial
cell characteristics and acquired ﬁbroblast-like properties.
In addition, EMT was accompanied by reduced cell-cell
adhesion, increased cell motility on ﬁbronectin-coated sur-
faces, and increased invasiveness in animals. Interestingly,
when Akt activity was inhibited, OSCC cells acquired
the mesenchymal-epithelial reverting transition and re-
expressed E-cadherin; hence, the epithelial characteristics
were restored [81]. This phenomenon is an important step
of cancer cells to dwell in the metastatic sites and adapt
to their new microenvironment. It was suggested that a
strategy involving Akt inhibition be a promising therapeutic
approach in controlling cancer invasion and metastasis in
OSCC patients.
TGFβ is a paradoxical cytokine in its functional role.
TGFβ acts as a tumor suppressor in normal epithelial cells
and cancer cells at their early stages of carcinogenesis.
As the carcinogenesis progresses, cancer cells can switch
their responses to TGFβ and utilize TGFβ as a potent
oncogenic activator [83]. Several studies have shown that
TGFβ mediatesEMTinvariousdevelopmentalprocessesand
human cancers, including OSCC [84]. A study by Qiao et
al. revealed that upon stimulation with recombinant TGFβ1,
Slug and MMP-9 were upregulated, while Snail expression
increased and fell, in concert with the expression of MMP-
2 in OSCC cells, suggesting that both Snail and Slug act
as regulators of TGFβ1-triggered EMT [85]. Interestingly,
a study by Richter et al. showed that EMT in OSCC was
mediated by multiple growth factors, including EGF and
TGFβ1[ 86]. In contrast to the eﬀect of treatment with either
EGF or TGFβ1, costimulation induced phenotype transition
in OSCC cells with up-regulation of vimentin and down-
regulation of E-cadherin. Moreover, OSCC cells displayed an
enhanced invasiveness and adhesion to type I-IV collagens.
Another study also demonstrated that the expression of
MMP-10 was increased following treatment of premalignant
human keratinocytes, HaCaT cells, with a combination ofISRN Oncology 7
TGFβ1a n dE G F[ 87]. TGFβ1 alone could upregulate plas-
minogen activator inhibitor type-1 (PAI-1) in HaCaT cells.
CDK2-AP1 (p12), a downstream eﬀector of TGFβ,c o u l d
also induce EMT of hamster cheek pouch carcinoma-1 cells
by promoting the expression of Twist-2 [88]. Interestingly,
those EMT cancer cells showed increased invasiveness but
decreasedmetastaticphenotype.Collectively,TGFβ andEGF
may play a complex role in EMT as well as modulating
ECM degradation and facilitating the progression of OSCC
carcinogenesis.
The Wnt/β-catenin pathway is one of the major signaling
pathways in cell proliferation, oncogenesis, and EMT. A
recent study showed that aberrant cytoplasmic accumulation
of β-catenin induced TCF/LEF-mediated transcriptional ac-
tivity, up-regulation of MMP-7, and induced EMT in OSCC
cells,hence,enhancinginvasionandmigrationofOSCCcells
[89]. Recently, Iamaroon et al. found an aberration of TGFβ
signaling pathway in OSCC as evidenced by a reduction or
deletion of Smad4 expression [90]. These ﬁndings suggest
that some OSCC might employ an alternative signaling
pathway, like the PI3K/Akt, MEK/ERK or Wnt/β-catenin
pathway.
Hypoxia has been found to play a critic role in EMT [91].
The hypoxic microenvironment, in particular, is common
to any cancer cells and can trigger EMT via regulating
the expression and activity levels of major transcriptional
repressors. In tongue SCC tissues, hypoxia inducible factor
(HIF)-1α,H I F - 2 α, and Twist-2 were overexpressed and
the overexpression of these molecules, except HIF-2α,w a s
associated with a shorter disease-free survival [92]. It was
suggested that coexpression of more than two markers from
HIF-1α and Twist2 be a signiﬁcant prognostic predictor in
patients with tongue SCC.
8. Conclusion
Oral squamous cell carcinoma is a devastating disease and
remains a major threat to global public health. Extensive
studies with impressive results have been performed and
elucidated the complex nature of OSCC carcinogenesis.
Emerging knowledge gained from studies on EMT in the
last decade has provided a better understanding of the
mechanisms of EMT in human cancers, including OSCC.
Undoubtedly, this knowledge will contribute signiﬁcant
advances to the biology of carcinogenesis, leading to devel-
opment of new biomarkers for diagnosis and prognosis and
targeted therapeutics for patients suﬀered from OSCC.
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